SG Americas Securities LLC Acquires 75,679 Shares of Hims & Hers Health, Inc. $HIMS

SG Americas Securities LLC lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 25.6% in the 4th quarter, Holdings Channel reports. The firm owned 371,553 shares of the company’s stock after acquiring an additional 75,679 shares during the period. SG Americas Securities LLC’s holdings in Hims & Hers Health were worth $12,064,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Virtus Advisers LLC bought a new stake in Hims & Hers Health during the second quarter valued at approximately $26,000. Quent Capital LLC bought a new position in shares of Hims & Hers Health in the 3rd quarter worth $28,000. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the 1st quarter valued at $30,000. Finally, Hilltop National Bank bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth $35,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

HIMS stock opened at $19.43 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The firm’s fifty day moving average is $21.73 and its 200 day moving average is $35.78. The firm has a market cap of $4.43 billion, a P/E ratio of 38.09, a P/E/G ratio of 2.34 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter last year, the company earned $0.11 EPS. The firm’s revenue was up 28.4% compared to the same quarter last year. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 9,217 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09. Following the completion of the sale, the chief financial officer directly owned 318,789 shares in the company, valued at $7,577,614.53. This represents a 2.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 134,984 shares of company stock worth $3,458,041 in the last ninety days. Corporate insiders own 13.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Leerink Partners upped their target price on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. TD Cowen lowered their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday. Bank of America raised Hims & Hers Health from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $12.50 to $23.00 in a research note on Tuesday, March 10th. Truist Financial reiterated a “hold” rating and issued a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $31.71.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Major commercial catalyst — HIMS announced availability of a broad suite of Novo Nordisk FDA‑approved GLP‑1 medications for eligible customers, expanding product mix and potential revenue/ARPU upside from higher‑price branded drugs. Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
• Positive Sentiment: Business model shift — coverage highlights HIMS moving toward a broader mix of branded, FDA‑approved GLP‑1s after the Novo collaboration and FDA shortage resolution, which could lift margins and reduce prior legal/commercial uncertainty. Hims & Hers shifts business model after Novo deal
• Neutral Sentiment: Analyst/features coverage and investor writeups (Seeking Alpha, USA Today sponsored pieces, Yahoo/Fool commentary) are framing a potential reset and longer‑term inflection, useful for context but not immediate proof of sustained upside. Hims & Hers: The Reset Before The Next Inflection
• Neutral Sentiment: Institutional positions remain large (Vanguard, Capital World, Farallon, etc.), which supports liquidity and means any moves could be amplified by institutional flows rather than retail noise. MarketBeat HIMS Coverage
• Negative Sentiment: Fresh analyst pressure — TD Cowen trimmed its price target to $23 and set a “hold”, and other outlets report lower targets/discounted valuations, which can trigger short‑term selling and lower investor conviction. TD Cowen price target cut (Benzinga)
• Negative Sentiment: Legal and governance overhang — a securities‑fraud investigation has been opened (Schall Law Firm), creating regulatory risk that can depress multiples until resolved. Fraud investigation announcement
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe sold ~9.2k shares recently; continued insider sales have been flagged by analysts and can sap market confidence, especially amid valuation compression. SEC Form 4 — Insider Sale

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.